Indeed, among treatment options for metastatic colorectal cancer (mCRC), in particular, are two anti-EGFR mAbs, cetuximab and panitumumab, currently indicated for the same subgroup of patients, those with RAS wild-type (wt) metastatic disease (2, 3). This evidence concerns the gene EGFR and metastatic neoplasm.